Company: GANX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001104659-25-110347
Chunk: 5

Company: Gain Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1F
Chunk 5
---
 328,327Total noncurrent liabilities​​​ 891,648​​ 872,989Total liabilities ​$ 5,062,250​$ 4,784,310​​​​​​​​Stockholders’ equity ​   ​   Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of September 30, 2025 and December 31, 2024​​$ —​$ —Common stock, $0.0001 par value: 100,000,000 shares authorized; 35,976,390 and 27,132,588 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively ​  3,599​  2,713Additional paid-in capital ​  102,161,036​  88,779,318Accumulated other comprehensive income (loss) ​  563,221​  (247,549)Accumulated deficit ​  (81,194,908)​  (60,783,717)Loss of the period ​  (15,623,518)​  (20,411,191)Total stockholders’ equity ​​ 5,909,430​​ 7,339,574Total liabilities and stockholders’ equity ​$ 10,971,680​$ 12,123,884

​

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

​